Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04854499 · ClinicalTrials.gov registry record · Phase 2
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 193
- Enrollment target
NCT04854499 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 193 participants.
The verdict
NCT04854499, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 193 participants
- Enrollment target
Study Summary
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in participants with head and neck squamous cell carcinoma (HNSCC).
Interventions
- DRUG Pembrolizumab
- DRUG Docetaxel
- DRUG Cisplatin
- DRUG 5-FU
- DRUG Magrolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2021-09-07 |
| Est. Completion | 2024-10-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04854499
The ClinicalTrials.gov registry entry for NCT04854499 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 193 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT04854499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04854499 about?
NCT04854499 is a clinical study titled "Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma". The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in participants with head and neck squamous cell carcinoma (HNSCC).
What is the current status of trial NCT04854499?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 193 participants. The study started on 2021-09-07. Estimated completion is 2024-10-02.
What interventions are being tested in trial NCT04854499?
The interventions under investigation include: Pembrolizumab (DRUG), Docetaxel (DRUG), Cisplatin (DRUG), 5-FU (DRUG), Magrolimab (DRUG).
Who is sponsoring clinical trial NCT04854499?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.